The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Stem cell transplantation conditioning in AML: making the decision between MAC and RIC
Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, FMedSci, University of Birmingham, Birmingham, UK, discusses the use of myeloablative conditioning (MAC) versus reduced-intensity conditioning (RIC) regimens for stem cell transplantation (SCT) in patients with acute myeloid leukemia (AML). Prof. Craddock recommends MAC for young and fit patients, whereas he suggests that RIC is a more suitable option for older patients due to the toxicity associated with MAC. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS, Abbvie
Research Funding: BMS
